Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1) Blocking Antibodies for Treatment of Patients with Cancer: Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
December 6, 2022
December 6, 2022
39b5200a-95fe-45d2-ac1a-170502282ac4
Related Documents
Bladder Cancer: Developing Drugs and Biologics for Adjuvant Treatment: Guidance for Industry
Guidance DocumentJune 28, 2022Office of the Commissioner
Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment: Guidance for Industry
Guidance DocumentJune 27, 2022Office of the Commissioner
Advanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues Guidance for Industry: Clinical/Medical
Guidance DocumentMay 27, 2022Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.